154 related articles for article (PubMed ID: 34236577)
1. Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus.
Hoshika Y; Kubota Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Maruyama M; Tanabe J; Shimizu W
Diabetes Ther; 2021 Aug; 12(8):2241-2248. PubMed ID: 34236577
[TBL] [Abstract][Full Text] [Related]
2. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
Mozawa K; Kubota Y; Hoshika Y; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Maruyama M; Tanabe J; Shimizu W
ESC Heart Fail; 2021 Oct; 8(5):4161-4173. PubMed ID: 34235875
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
5. Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale.
Kubota Y; Yamamoto T; Tara S; Tokita Y; Yodogawa K; Iwasaki Y; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Sato N; Tanabe J; Shimizu W
Diabetes Ther; 2018 Oct; 9(5):2107-2116. PubMed ID: 30097993
[TBL] [Abstract][Full Text] [Related]
6. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Tripolt NJ; Kolesnik E; Pferschy PN; Verheyen N; Ablasser K; Sailer S; Alber H; Berger R; Kaulfersch C; Leitner K; Lichtenauer M; Mader A; Moertl D; Oulhaj A; Reiter C; Rieder T; Saely CH; Siller-Matula J; Weidinger F; Zechner PM; von Lewinski D; Sourij H;
Am Heart J; 2020 Mar; 221():39-47. PubMed ID: 31901799
[TBL] [Abstract][Full Text] [Related]
7. Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.
Kario K; Okada K; Kato M; Nishizawa M; Yoshida T; Asano T; Uchiyama K; Niijima Y; Katsuya T; Urata H; Osuga JI; Fujiwara T; Yamazaki S; Tomitani N; Kanegae H
Circulation; 2019 Apr; 139(18):2089-2097. PubMed ID: 30586745
[TBL] [Abstract][Full Text] [Related]
8. Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial.
Hoshika Y; Kubota Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Maruyama M; Tanabe J; Shimizu W
J Card Fail; 2022 Jan; 28(1):56-64. PubMed ID: 34425223
[TBL] [Abstract][Full Text] [Related]
9. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
[TBL] [Abstract][Full Text] [Related]
10. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
11. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial.
Benedikt M; Mangge H; Aziz F; Curcic P; Pailer S; Herrmann M; Kolesnik E; Tripolt NJ; Pferschy PN; Wallner M; Zirlik A; Sourij H; von Lewinski D
Cardiovasc Diabetol; 2023 Jul; 22(1):166. PubMed ID: 37407956
[TBL] [Abstract][Full Text] [Related]
12. EMMY: The continued expansion of clinical applications of SGLT2 inhibitors.
Kotit S
Glob Cardiol Sci Pract; 2023 Jan; 2023(1):e202305. PubMed ID: 36890845
[No Abstract] [Full Text] [Related]
13. Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design.
Fujiki S; Iijima K; Okabe M; Niwano S; Tsujita K; Naito S; Ando K; Kusano K; Kato R; Nitta J; Miura T; Mitsuhashi T; Kario K; Kondo Y; Ieda M; Hagiwara N; Murohara T; Takahashi K; Tomita H; Takeishi Y; Anzai T; Shimizu W; Watanabe M; Morino Y; Kato T; Tada H; Nakagawa Y; Yano M; Maemura K; Kimura T; Yoshida H; Ota K; Tanaka T; Kitamura N; Node K; Aizawa Y; Shimizu I; Izumi D; Ozaki K; Minamino T;
Diabetes Ther; 2020 Nov; 11(11):2739-2755. PubMed ID: 32968947
[TBL] [Abstract][Full Text] [Related]
14. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes.
Yasui A; Lee G; Hirase T; Kaneko T; Kaspers S; von Eynatten M; Okamura T
Diabetes Ther; 2018 Apr; 9(2):863-871. PubMed ID: 29488164
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
Damman K; Beusekamp JC; Boorsma EM; Swart HP; Smilde TDJ; Elvan A; van Eck JWM; Heerspink HJL; Voors AA
Eur J Heart Fail; 2020 Apr; 22(4):713-722. PubMed ID: 31912605
[TBL] [Abstract][Full Text] [Related]
18. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
19. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.
Kolwelter J; Kannenkeril D; Linz P; Jung S; Nagel AM; Bosch A; Ott C; Bramlage P; Nöh L; Schiffer M; Uder M; Achenbach S; Schmieder RE
Clin Res Cardiol; 2023 Jan; 112(1):134-144. PubMed ID: 36289063
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
